166 related articles for article (PubMed ID: 17606704)
1. Triggering tumor immunity through angiogenesis targeting.
Jinushi M; Dranoff G
Clin Cancer Res; 2007 Jul; 13(13):3762-4. PubMed ID: 17606704
[No Abstract] [Full Text] [Related]
2. Cancer: looking outside the genome.
Folkman J; Hahnfeldt P; Hlatky L
Nat Rev Mol Cell Biol; 2000 Oct; 1(1):76-9. PubMed ID: 11413493
[No Abstract] [Full Text] [Related]
3. Endogenous inhibitors of angiogenesis.
Folkman J
Harvey Lect; 1996-1997; 92():65-82. PubMed ID: 15372744
[No Abstract] [Full Text] [Related]
4. Molecular mechanisms and therapeutic development of angiogenesis inhibitors.
Cao Y
Adv Cancer Res; 2008; 100():113-31. PubMed ID: 18620094
[TBL] [Abstract][Full Text] [Related]
5. Antiangiogenic therapy and p53.
Hammond EM; Giaccia AJ
Science; 2002 Jul; 297(5581):471; discussion 471. PubMed ID: 12142499
[No Abstract] [Full Text] [Related]
6. Thalidomide: dual benefits in palliative medicine and oncology.
Davis MP; Dickerson ED
Am J Hosp Palliat Care; 2001; 18(5):347-51. PubMed ID: 11565189
[TBL] [Abstract][Full Text] [Related]
7. Chapter 6. Mouse models to investigate anti-cancer effects of VEGF inhibitors.
Crawford Y; Ferrara N
Methods Enzymol; 2008; 445():125-39. PubMed ID: 19022058
[TBL] [Abstract][Full Text] [Related]
8. Targeting vessel abnormalization in cancer.
Garber K
J Natl Cancer Inst; 2007 Jul; 99(13):991-2, 995. PubMed ID: 17596567
[No Abstract] [Full Text] [Related]
9. Tumor necrosis factor-mediated interactions between inflammatory response and tumor vascular bed.
ten Hagen TL; Seynhaeve AL; Eggermont AM
Immunol Rev; 2008 Apr; 222():299-315. PubMed ID: 18364010
[TBL] [Abstract][Full Text] [Related]
10. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies.
Shojaei F; Ferrara N
Drug Resist Updat; 2008 Dec; 11(6):219-30. PubMed ID: 18948057
[TBL] [Abstract][Full Text] [Related]
11. [Inhibition of the VEGF receptor system with tyrosine kinase inhibitors. Angiogenesis inhibition in oncology].
Mross K
Pharm Unserer Zeit; 2008; 37(5):404-15. PubMed ID: 18729270
[No Abstract] [Full Text] [Related]
12. [Neoplasms under control with the help of vascular treatment?].
Laurén J; Alitalo K
Duodecim; 2000; 116(7):705-11. PubMed ID: 12078136
[No Abstract] [Full Text] [Related]
13. [Angiogenesis: all a radiation oncologist should know].
Mazeron R; Bourhis J; Deutsch E
Cancer Radiother; 2008 Jan; 12(1):50-60. PubMed ID: 18243753
[TBL] [Abstract][Full Text] [Related]
14. Targeting vessels to treat hepatocellular carcinoma.
Romanque P; Piguet AC; Dufour JF
Clin Sci (Lond); 2008 Apr; 114(7):467-77. PubMed ID: 18302534
[TBL] [Abstract][Full Text] [Related]
15. [Development of angiogenesis inhibitory combination therapies for treatment of renal cell carcinoma].
Bartsch G; Eggert K; Soker S; Fiedler W; Laack E; Volkmer BG; Gschwend J; Bokemeyer C; Hautmann R; Schuch G
Urologe A; 2007 Sep; 46(9):1289-90. PubMed ID: 17624513
[No Abstract] [Full Text] [Related]
16. [Antibody therapy in hematology and oncology--2].
Kneba M; Schrader C; Köhne H
Med Klin (Munich); 2009 Jan; 104(1):28-49. PubMed ID: 19142594
[No Abstract] [Full Text] [Related]
17. [Systemic and cellular pathways of anti-tumor action of plant adaptogenes].
Arushanian EB
Vopr Onkol; 2009; 55(1):15-23. PubMed ID: 19435193
[No Abstract] [Full Text] [Related]
18. Therapeutic strategies using inhibitors of angiogenesis.
O'Reilly MS
Methods Mol Biol; 2003; 223():599-634. PubMed ID: 12777753
[No Abstract] [Full Text] [Related]
19. Inhibitors of angiogenesis: new hopes for oncologists, new challenges for anesthesiologists.
Libert N; Tourtier JP; Védrine L; Chargari C
Anesthesiology; 2010 Sep; 113(3):704-12. PubMed ID: 20693871
[No Abstract] [Full Text] [Related]
20. Tumor angiogenesis--a potential target in cancer chemoprevention.
Bhat TA; Singh RP
Food Chem Toxicol; 2008 Apr; 46(4):1334-45. PubMed ID: 17919802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
